SCHEMBL25820146

SCHEMBL25820146

Cc1cc(CC(C)C)c2cc(N3CCOC(C)(C)C3)ccc2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LATS1 O95835 1/20 0.37
NCF1 P14598 1/20 0.36
MAP3K7 O43318 1/20 0.35
KMT2A Q03164 3/20 0.35
POLB P06746 2/20 0.35
MEN1 O00255 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PRKDC P78527 2/20 0.35
MAPT P10636 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
SYK P43405 1/20 0.34
MAP3K12 Q12852 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25820175 0.84 KMT2A (0.49) NCF1KMT2APOLBMEN1KDM4E
SCHEMBL25820148 0.84 LATS1 (0.38) LATS1MAP3K7KMT2AMEN1PRKDC
SCHEMBL23999899 0.81 LMNA (0.46) LATS1NCF1MAP3K7KMT2APOLB
SCHEMBL25821152 0.81 NCF1 (0.47) NCF1KMT2APOLBMEN1KDM4E
SCHEMBL25820170 0.81 NCF1 (0.44) NCF1KMT2AMEN1KDM4EALDH1A1
SCHEMBL25820102 0.81 NCF1 (0.41) NCF1KMT2AMEN1KDM4EALDH1A1
SCHEMBL23999730 0.80 KMT2A (0.43) LATS1NCF1KMT2APOLBMEN1
SCHEMBL25821148 0.79 MAPT (0.34) NCF1KMT2APOLBMEN1KDM4E
SCHEMBL23999418 0.79 MAPT (0.44) LATS1NCF1KMT2APOLBMEN1
SCHEMBL24003898 0.79 LATS1 (0.39) LATS1NCF1MAP3K7KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR LATS1 764/4885NCF1 1223/4885MAP3K7 93/4885
US-20230219927-A1 AKT3 MODULATORS AKT3, AKT2, PIK3CA LATS1 1192/4885NCF1 1002/4885MAP3K7 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.